BHC Stock Cash Flow Statements

Bausch Health Companies Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Bausch Health Companies Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2013-09-30	2012-09-30

cash flows from operating activities
net income	128,000,000	-86,000,000	98,000,000	-92,000,000	-1,000,000	-77,000,000	-47,000,000	-382,000,000	27,000,000	-209,000,000	-410,000,000	403,000,000	-139,000,000	-66,000,000	72,000,000	191,000,000	-593,000,000	-607,000,000	-152,000,000	70,000,000	-325,000,000	-152,000,000	-1,517,000,000	-48,000,000	-170,000,000	-48,000,000	-342,000,000	-351,000,000	-760,000,000	-2,691,000,000	512,000,000	1,300,000,000	-37,000,000	629,000,000	-982,841,000	29,252,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization of intangible assets	307,000,000	305,000,000	307,000,000	322,000,000	318,000,000	320,000,000	329,000,000	301,000,000	315,000,000	319,000,000	360,000,000	335,000,000	347,000,000	352,000,000	363,000,000	382,000,000	404,000,000	403,000,000	428,000,000	436,000,000	480,000,000	481,000,000	492,000,000	520,000,000	531,000,000	532,000,000	546,000,000	703,000,000	784,000,000	786,000,000	819,000,000	698,000,000	667,000,000	674,000,000
amortization and write-off of debt premiums, discounts and issuance costs	41,000,000	15,000,000		13,000,000	14,000,000	14,000,000		28,000,000	12,000,000	11,000,000		22,000,000	50,000,000	14,000,000		17,000,000	12,000,000	13,000,000		13,000,000	17,000,000	15,000,000		17,000,000	15,000,000	17,000,000
asset impairments			23,000,000	0	5,000,000	1,000,000		4,000,000	37,000,000	13,000,000										2,000,000	1,000,000	14,000,000	26,000,000	33,000,000	13,000,000	3,000,000	134,000,000	89,000,000	301,000,000	44,000,000	85,000,000	406,000,000	85,000,000	138,000,000
acquisition-related contingent consideration	-29,000,000	-11,000,000	-5,000,000	25,000,000	-4,000,000	-2,000,000	19,000,000	26,000,000	-17,000,000	31,000,000	27,000,000	4,000,000	-5,000,000	3,000,000	3,000,000			-9,000,000	22,000,000	2,000,000	11,000,000	13,000,000	10,000,000	3,000,000	20,000,000	-21,000,000	14,000,000	-19,000,000	-6,000,000	2,000,000	8,000,000	-238,000,000	-49,000,000	-10,000,000	-38,664,000	-2,099,000
allowances for losses on trade receivable and inventories	10,000,000	26,000,000		11,000,000	17,000,000	15,000,000		11,000,000	22,000,000	10,000,000		17,000,000	5,000,000	14,000,000		16,000,000	18,000,000	17,000,000		18,000,000	19,000,000	15,000,000		19,000,000	14,000,000	13,000,000		15,000,000	16,000,000	17,000,000		23,000,000	24,000,000	24,000,000
deferred income taxes	-42,000,000	-9,000,000	170,000,000	-3,000,000	-44,000,000	-57,000,000	84,000,000	-3,000,000			19,000,000	-96,000,000	-16,000,000	-83,000,000	-88,000,000	-17,000,000	-106,000,000	-14,000,000	-262,000,000	-19,000,000	-124,000,000	-70,000,000	3,000,000	-92,000,000	-25,000,000	-116,000,000	-142,000,000	40,000,000	-2,000,000	-40,000,000	-1,401,000,000	-1,778,000,000	-253,000,000	-954,000,000	-122,391,000	-101,243,000
net gain on sale of assets			0			-4,000,000	1,000,000	-5,000,000			-2,000,000	0				21,000,000	0	-23,000,000
adjustments to accrued legal settlements	8,000,000	-3,000,000		188,000,000	21,000,000	6,000,000				1,000,000		0
payments of accrued legal settlements	-87,000,000	-19,000,000	-8,000,000	-218,000,000	-1,000,000	-3,000,000	-7,000,000	-1,000,000	-1,000,000	-1,000,000	0	-1,212,000,000	0	-360,000,000	-207,000,000	-15,000,000	-11,000,000	-118,000,000	-86,000,000	-48,000,000	-31,000,000	-3,000,000	-11,000,000	-3,000,000	0	-1,000,000	-2,000,000	-2,000,000	-50,000,000	-170,000,000	0	-8,000,000			11,578,000	-35,987,000
share-based compensation	46,000,000	43,000,000	43,000,000	38,000,000	36,000,000	33,000,000	29,000,000	29,000,000	33,000,000	41,000,000	35,000,000	33,000,000	26,000,000	32,000,000	33,000,000	33,000,000	31,000,000	31,000,000	24,000,000	27,000,000	27,000,000	27,000,000	25,000,000	26,000,000	27,000,000	24,000,000	22,000,000	22,000,000	22,000,000	21,000,000	17,000,000	19,000,000	23,000,000	28,000,000	8,619,000	3,391,000
gain excluded from hedge effectiveness	-3,000,000	-3,000,000	-3,000,000	-4,000,000	-3,000,000	-3,000,000	-3,000,000	-4,000,000	-3,000,000	-3,000,000	-3,000,000				-3,000,000	-6,000,000	-5,000,000	-6,000,000	-6,000,000	-6,000,000
gain on extinguishment of debt			0	0	-12,000,000	-11,000,000
payments of contingent consideration adjustments, including accretion	-2,000,000	-2,000,000	-3,000,000	-2,000,000	-3,000,000	-2,000,000	-6,000,000	-1,000,000			-1,000,000	0			0	-8,000,000							0	0			0
amortization of interim contract and inventory step-up resulting from acquisitions	20,000,000	22,000,000	21,000,000	21,000,000	20,000,000	20,000,000
foreign exchange and other	-21,000,000	-2,000,000	36,000,000	-15,000,000	-14,000,000	-4,000,000
changes in operating assets and liabilities:
trade receivables	-91,000,000	110,000,000	-104,000,000	23,000,000	-72,000,000	-63,000,000	-19,000,000	-231,000,000	-53,000,000	108,000,000	-31,000,000	-133,000,000	-90,000,000	197,000,000	-52,000,000	-129,000,000	-108,000,000	60,000,000	103,000,000	-356,000,000	354,000,000	69,000,000	-71,000,000	54,000,000	-33,000,000	89,000,000	160,000,000	-72,000,000	-76,000,000	204,000,000	79,000,000	-114,000,000	20,000,000	432,000,000
inventories	7,000,000	-30,000,000	-49,000,000	-42,000,000	-32,000,000	-144,000,000	-100,000,000	-62,000,000	-32,000,000	-128,000,000	-4,000,000	-56,000,000	-65,000,000	-73,000,000	46,000,000	-15,000,000	-12,000,000	-35,000,000	101,000,000	10,000,000	-94,000,000	-94,000,000	-4,000,000	-84,000,000	-53,000,000	-68,000,000	3,000,000	4,000,000			6,000,000			-38,000,000	-12,190,000	6,646,000
prepaid expenses and other current assets	12,000,000	-46,000,000	13,000,000	1,000,000	-2,000,000	121,000,000	-148,000,000	-21,000,000	-21,000,000	-33,000,000	-34,000,000	16,000,000	-15,000,000	-33,000,000	-41,000,000	16,000,000			1,000,000	27,000,000	2,000,000	-18,000,000	-15,000,000	15,000,000	16,000,000	-15,000,000	-19,000,000	23,000,000	-6,000,000	-70,000,000	1,000,000	12,000,000	18,000,000	2,000,000	44,432,000	-7,457,000
accounts payable, accrued and other liabilities	163,000,000	-99,000,000	24,000,000	144,000,000	138,000,000	51,000,000	97,000,000	166,000,000	-97,000,000	-8,000,000	47,000,000	-96,000,000	49,000,000	-75,000,000	-170,000,000	46,000,000	130,000,000	115,000,000	-185,000,000	70,000,000	-271,000,000	-85,000,000	-116,000,000	26,000,000	-55,000,000	-4,000,000	-228,000,000	84,000,000	-66,000,000	89,000,000	88,000,000	143,000,000	-40,000,000	196,000,000
net cash from operating activities	289,000,000	211,000,000	601,000,000	405,000,000	380,000,000	211,000,000	390,000,000	282,000,000	206,000,000	154,000,000	475,000,000	-1,263,000,000	123,000,000	-63,000,000	24,000,000	564,000,000	395,000,000	443,000,000	394,000,000	256,000,000	200,000,000	261,000,000	234,000,000	515,000,000	339,000,000	413,000,000	319,000,000	522,000,000	222,000,000	438,000,000	578,000,000	490,000,000	268,000,000	954,000,000	-103,316,000	-87,775,000
capex	-99,000,000	-115,000,000	-106,000,000	-71,000,000	-78,000,000	-82,000,000	-98,000,000	-42,000,000	-28,000,000	-47,000,000	-66,000,000	-54,000,000	-52,000,000	-46,000,000	-78,000,000	-63,000,000	-62,000,000	-66,000,000	-80,000,000	-81,000,000	-69,000,000	-72,000,000	-78,000,000	-83,000,000	-62,000,000	-47,000,000	-62,000,000	-32,000,000	-30,000,000	-33,000,000	-53,000,000	-43,000,000	-37,000,000	-38,000,000	-12,171,000	-43,468,000
free cash flows	190,000,000	96,000,000	495,000,000	334,000,000	302,000,000	129,000,000	292,000,000	240,000,000	178,000,000	107,000,000	409,000,000	-1,317,000,000	71,000,000	-109,000,000	-54,000,000	501,000,000	333,000,000	377,000,000	314,000,000	175,000,000	131,000,000	189,000,000	156,000,000	432,000,000	277,000,000	366,000,000	257,000,000	490,000,000	192,000,000	405,000,000	525,000,000	447,000,000	231,000,000	916,000,000	-115,487,000	-131,243,000
cash flows from investing activities
acquisitions and other investments	0	-12,000,000	-91,000,000					-1,856,000,000	0	-31,000,000
purchases of property, plant and equipment	-99,000,000	-115,000,000	-106,000,000	-71,000,000	-78,000,000	-82,000,000	-98,000,000	-42,000,000	-28,000,000	-47,000,000	-66,000,000	-54,000,000	-52,000,000	-46,000,000	-78,000,000	-63,000,000	-62,000,000	-66,000,000	-80,000,000	-81,000,000	-69,000,000	-72,000,000	-78,000,000	-83,000,000	-62,000,000	-47,000,000	-62,000,000	-32,000,000	-30,000,000	-33,000,000	-53,000,000	-43,000,000	-37,000,000	-38,000,000	-12,171,000	-43,468,000
acquisition of intangible assets and other assets	-1,000,000	-9,000,000	-1,000,000	0	-1,000,000	-1,000,000																							-61,000,000	-14,000,000	-19,000,000	-5,000,000	-10,000,000	-131,000,000	27,657,000
purchases of marketable securities	-1,000,000	-4,000,000	-5,000,000	-2,000,000	-2,000,000	-3,000,000	-14,000,000	-2,000,000	2,000,000	-13,000,000	-2,000,000	-1,000,000	-9,000,000	-5,000,000	-5,000,000	-3,000,000	-6,000,000	-5,000,000	-1,000,000	-1,000,000	0	-2,000,000	-8,000,000	-3,000,000	-3,000,000	-2,000,000	-2,000,000	-1,000,000			-3,000,000	-3,000,000
proceeds from sale of marketable securities	1,000,000	4,000,000	3,000,000	4,000,000	1,000,000	6,000,000	13,000,000	4,000,000	-2,000,000	11,000,000	2,000,000	7,000,000	7,000,000	6,000,000	4,000,000	3,000,000	6,000,000	2,000,000	1,000,000	1,000,000	4,000,000	2,000,000	7,000,000	2,000,000	0	1,000,000	2,000,000	1,000,000	2,000,000	2,000,000	0	1,000,000
proceeds from sale of assets and businesses, net of costs to sell			0	5,000,000	1,000,000	1,000,000	0	4,000,000							0	644,000,000	21,000,000	4,000,000	0	0	0	21,000,000	1,000,000	11,000,000	8,000,000	25,000,000	2,000,000	38,000,000	2,000,000	-8,000,000	190,000,000	919,000,000	827,000,000	1,317,000,000
interest settlements from cross-currency swaps	0	6,000,000	0	7,000,000	0	6,000,000	0	7,000,000	0	6,000,000						12,000,000	0	11,000,000	0	12,000,000	0	11,000,000
net cash from investing activities	-100,000,000	-130,000,000	-200,000,000	-102,000,000	-79,000,000	-73,000,000	-148,000,000	-1,889,000,000	-30,000,000	-78,000,000	-136,000,000	-53,000,000	-58,000,000	-56,000,000	-80,000,000	588,000,000	-43,000,000	-56,000,000	-84,000,000	-70,000,000	-67,000,000	-40,000,000	-85,000,000	-73,000,000	-58,000,000	-203,000,000	-62,000,000	5,000,000	-91,000,000	-48,000,000	90,000,000	869,000,000	780,000,000	1,148,000,000	-3,937,376,000	178,745,000
cash flows from financing activities
issuance of long-term debt, net of discounts	10,372,000,000	50,000,000	506,000,000	0	80,000,000	75,000,000	146,000,000	2,690,000,000	300,000,000	155,000,000	355,000,000	161,000,000	5,334,000,000	986,000,000	524,000,000	-3,000,000	1,582,000,000	-3,000,000	1,979,000,000	-1,000,000	1,480,000,000	-3,000,000
repayments of long-term debt	-9,967,000,000	-168,000,000	-411,000,000	-164,000,000	-495,000,000	-390,000,000	-203,000,000	-817,000,000	-411,000,000	-279,000,000	-622,000,000	-141,000,000	-6,598,000,000	-485,000,000	-240,000,000	-1,100,000,000	-1,900,000,000	-200,000,000	-2,480,000,000	-100,000,000	-1,603,000,000	-1,459,000,000	-450,000,000	-453,000,000	-1,882,000,000	-1,621,000,000	-1,901,000,000	-364,000,000	-6,105,000,000	-1,731,000,000	-4,954,000,000	-1,410,000,000	-220,000,000	-7,619,000,000	-4,606,318,000	96,118,000
payments of employee withholding taxes related to share-based awards	-3,000,000	-16,000,000		-5,000,000	-4,000,000	-14,000,000		-8,000,000	-3,000,000	-12,000,000		-1,000,000	-4,000,000	-25,000,000		-3,000,000	-4,000,000	-41,000,000		-1,000,000	-5,000,000	-24,000,000		-1,000,000	-5,000,000	-34,000,000
payments of acquisition-related contingent consideration	-5,000,000	-7,000,000	-7,000,000	-8,000,000	-5,000,000	-7,000,000	-18,000,000	-6,000,000	-4,000,000	-7,000,000	-7,000,000	-6,000,000	-5,000,000	-8,000,000	-6,000,000	-36,000,000	-35,000,000	-6,000,000	-5,000,000	-7,000,000	-6,000,000	-17,000,000		-7,000,000	-11,000,000	-9,000,000
payments of financing costs	-31,000,000	-5,000,000	2,000,000	-3,000,000	0	-4,000,000	0	-35,000,000			0	-37,000,000	-33,000,000	-1,000,000	0	-10,000,000	-34,000,000	-4,000,000	0	0	-21,000,000	-18,000,000	-2,000,000	0			-40,000,000	-3,000,000	-39,000,000	-20,000,000	-71,000,000	0	-1,000,000	-38,000,000
other			-2,000,000				-10,000,000	-7,000,000	10,000,000	-4,000,000	0	-15,000,000	-6,000,000	10,000,000	-8,000,000	-9,000,000	-6,000,000	-18,000,000	-11,000,000	2,000,000	-2,000,000	-7,000,000	9,000,000	11,000,000	7,000,000	9,000,000	2,000,000	-17,000,000	1,000,000	-3,000,000	-2,000,000	-22,000,000	-1,000,000	-1,000,000	-1,169,000	-5,520,000
net cash from financing activities	358,000,000	-146,000,000	85,000,000	-189,000,000	-424,000,000	-340,000,000	-79,000,000	1,816,000,000	-120,000,000	-142,000,000	-276,000,000	-36,000,000	-630,000,000	468,000,000	275,000,000	-1,157,000,000	-388,000,000	-243,000,000	-503,000,000	-117,000,000	-153,000,000	-1,521,000,000	2,255,000,000	-474,000,000	-188,000,000	-150,000,000	-502,000,000	-386,000,000	-177,000,000	-288,000,000	-1,842,000,000	-1,430,000,000	-249,000,000	-1,442,000,000	-37,603,000	-300,430,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	39,000,000	21,000,000
net increase in cash, cash equivalents and restricted cash														341,000,000
cash, cash equivalents and restricted cash, beginning of period	0	1,201,000,000												2,119,000,000		0	0	1,816,000,000
cash, cash equivalents and restricted cash, end of period	586,000,000	1,157,000,000		127,000,000	-132,000,000	755,000,000								2,460,000,000
cash and cash equivalents	593,000,000	1,134,000,000		124,000,000	-138,000,000	733,000,000		181,000,000	61,000,000	518,000,000		-173,000,000	-590,000,000	1,249,000,000		48,000,000	-37,000,000	679,000,000		81,000,000	-16,000,000	912,000,000		-53,000,000	96,000,000	782,000,000
restricted cash	-7,000,000	23,000,000		3,000,000	6,000,000	22,000,000		11,000,000	-4,000,000	13,000,000
net decrease in cash, cash equivalents and restricted cash		-44,000,000
amortization and write-off of debt discounts and debt issuance costs																											17,000,000	18,000,000	21,000,000	23,000,000	51,000,000	34,000,000	23,000,000	43,000,000	-5,707,000
goodwill impairment																													0	2,213,000,000	0
allowances for losses on trade receivables and inventories
additions to accrued legal settlements															35,000,000	2,000,000				4,000,000	120,000,000	23,000,000			1,000,000	2,000,000			-1,000,000	11,000,000				76,000,000	148,477,000
third party fees paid in connection with the 2022 exchange
proceeds from b+l initial public offering, net of costs											0
payment of employee withholding taxes related to share-based awards
effect of exchange rate changes on cash and cash equivalents														-8,000,000	-4,000,000	-9,000,000	7,000,000	-13,000,000	21,000,000	12,000,000	4,000,000	-21,000,000	13,000,000	-21,000,000	3,000,000	1,000,000	-5,000,000	-6,000,000	-25,000,000	10,000,000	2,000,000	15,000,000	16,000,000	8,000,000	9,598,000	7,137,000
net increase in cash, cash equivalents, restricted cash and other settlement deposits			451,000,000				182,000,000			-60,000,000	94,000,000	-1,382,000,000
cash, cash equivalents, restricted cash and other settlement deposits, beginning of year
cash, cash equivalents, restricted cash and other settlement deposits, end of year
cash and cash equivalents, end of year
restricted cash and other settlement deposits, end of year
cash, cash equivalents and restricted cash, end of year
goodwill impairments												119,000,000				0	0	469,000,000
effect of exchange rate changes on cash, cash equivalents and other				13,000,000	-9,000,000	-5,000,000		-17,000,000	1,000,000	6,000,000		-30,000,000
cash, cash equivalents, restricted cash and other settlement deposits, beginning of period				0	0	962,000,000	0	0	0	591,000,000	0	0
net (gain) loss on sale of assets
net decrease in cash, cash equivalents, restricted cash and other settlement deposits					-132,000,000	-207,000,000
third party fees paid in connection with the exchange offer							0	0			-3,000,000
asset impairments, including loss on assets held for sale											0	1,000,000	6,000,000	8,000,000	21,000,000	18,000,000	47,000,000	148,000,000
acquisition of businesses, net of cash acquired																							0	0	0	-180,000,000	0	0	0	5,000,000					-3,925,868,000	208,653,000
cash, cash equivalents, restricted cash and other settlement deposits, end of period							182,000,000	192,000,000	57,000,000	531,000,000	94,000,000	-1,382,000,000
foreign exchange gain										6,000,000													-1,000,000	10,000,000				-1,000,000	10,000,000	-25,000,000		-13,000,000	-39,000,000	-31,000,000		-2,943,000
payments for intangible and other assets								-4,000,000	-3,000,000	-4,000,000		-5,000,000	-4,000,000	-11,000,000		-5,000,000	-2,000,000	-2,000,000		-1,000,000				0
foreign exchange loss														-2,000,000	-2,000,000	1,000,000	-5,000,000	12,000,000				16,000,000
(gain) loss on extinguishment of debt											-192,000,000	-570,000,000
foreign exchange (gain) loss
restricted cash and other settlement deposits												-1,209,000,000	9,000,000	1,211,000,000
net proceeds from b+l initial public offering, net of costs
cash and cash equivalents, held for sale																	8,000,000	54,000,000
reductions to accrued legal settlements														-1,000,000
loss on extinguishment of debt															0	12,000,000	45,000,000	5,000,000	8,000,000	0	27,000,000	24,000,000	2,000,000	0	33,000,000	7,000,000	44,000,000	0	48,000,000	27,000,000	57,000,000	1,000,000	0	64,000,000
gain on disposal of assets																																				-795,000
settlements from cross-currency swaps
borrowings of short-term debt
repayments of short-term debt																			0				0	-4,000,000			-2,000,000	0	0	-1,000,000	0	-1,000,000
net increase in cash and cash equivalents and restricted cash and other settlement deposits
cash and cash equivalents and restricted cash and other settlement deposits, beginning of year
cash and cash equivalents and restricted cash and other settlement deposits, end of year
proceeds from the issuances of short-term debt																				0				0
net increase in cash, cash equivalents, restricted cash and cash and cash equivalents held for sale																	-29,000,000	131,000,000
cash, cash equivalents, restricted cash and cash and cash equivalents held for sale, end of period																	-29,000,000	1,947,000,000
restricted cash, current																	0	1,214,000,000		0	0	1,011,000,000		0	0	2,000,000
(gain) loss on disposal of assets
additions (reductions) to accrued legal settlements																							1,389,000,000
payments of deferred consideration																											0	0
net increase in cash and cash equivalents and restricted cash																			-172,000,000	81,000,000	-16,000,000	-1,321,000,000	2,417,000,000	-53,000,000	96,000,000	61,000,000	-250,000,000	135,000,000			-1,172,000,000
cash and cash equivalents and restricted cash, beginning of year
cash and cash equivalents and restricted cash, end of year
restricted cash, end of year
gain on sale of assets																				0	0	-1,000,000			1,000,000	-10,000,000
cash and cash equivalents and restricted cash, beginning of period																				0	0	3,244,000,000		0	0	723,000,000		0	0	797,000,000	0
cash and cash equivalents and restricted cash, end of period																				81,000,000	-16,000,000	1,923,000,000		-53,000,000	96,000,000	784,000,000		135,000,000			-1,172,000,000
interest expense on cross-currency swaps																						-6,000,000
(gain) loss on disposal of assets and businesses
insurance proceeds for legal settlement																															0	40,000,000
payment of share-based awards tax withholding
payments of contingent consideration																											-11,000,000	-8,000,000	-7,000,000	-11,000,000	-11,000,000	-9,000,000	-17,000,000	-8,000,000	46,755,000	14,692,000
(gain) loss on sale of assets
net proceeds from the issuances of long-term debt																								-5,000,000	1,729,000,000	1,514,000,000
debt extinguishment costs																										-1,000,000
acquisition accounting adjustment on inventory sold																																			122,882,000	-4,285,000
gain on disposal of assets and businesses
(reductions) additions to accrued legal settlements																											3,000,000
reduction of cash due to deconsolidation
proceeds from exercise of stock options																											1,000,000								644,000	3,298,000
payment of employee withholding tax upon vesting of share-based awards																													-3,000,000	-5,000,000	0	-1,000,000
gain on disposals of assets and businesses																																-328,000,000
issuances of long-term debt, net of discount
payments of employee withholding tax upon vesting of share-based awards																																			296,000	2,534,000
restricted cash, noncurrent
payment of contingent consideration adjustments, including accretion																																-1,000,000	-1,000,000	-1,000,000
issuance of long-term debt, net of discount																													5,993,000,000	1,481,000,000	3,193,000,000	-1,000,000	-2,000,000	6,234,000,000	6,825,121,000	-518,472,000
cash and cash equivalents, end of period																													-71,000,000	909,000,000	-244,000,000	-250,000,000	4,000,000	1,210,000,000	-1,943,043,000	-137,536,000
restricted cash, end of period																															-851,000,000
net increase in cash and cash equivalents																														112,000,000				668,000,000	-4,068,697,000	-202,323,000
net settlement of assumed derivative contracts
repayments of convertible notes assumed
issuance of common stock																																			-2,272,620,000
repurchases of common shares
loss on deconsolidation
restricted cash included in other non-current assets, end of period
additions (reduction) to accrued legal settlements
restricted cash included in current assets, end of period
(gain) loss on disposals of assets and businesses																																		-317,000,000
short-term debt borrowings																																			-9,407,000	-3,306,000
short-term debt repayments																																		-1,000,000	-14,403,000	16,762,000
tax benefit from share-based compensation
acquisition of noncontrolling interest																																		-9,000,000
cash and cash equivalents, beginning of period																																		542,000,000	2,125,654,000	64,787,000
depreciation and amortization, including impairments of finite-lived intangible assets
in-process research and development impairments
allowances for losses on accounts receivable and inventories																																			4,544,000	5,113,000
deferred income tax (benefit) expense
proceeds from sales and maturities of short-term investments
settlement of foreign currency forward exchange contracts
increase in restricted cash and cash equivalents
non-cash investing and financing activities
acquisition of businesses, contingent and deferred consideration obligations at fair value
acquisition of businesses, debt assumed																																			-4,217,113,000
in-process research and development impairments and other charges																																			119,151,000
loss on disposal of assets
tax benefits from stock options exercised																																			-20,334,000	515,000
gain on sale of marketable securities
payment of accreted interest on contingent consideration																																			-1,113,000	346,000
accounts receivable																																			97,736,000	-190,829,000
accounts payable, accrued liabilities and other liabilities																																			-101,233,000	93,387,000
proceeds from sales and maturities of marketable securities
purchases of marketable securities and other investments
proceeds from sale of assets
increase in restricted cash
repurchases of convertible debt
cash settlement of convertible debt
distributions to noncontrolling interest
payments of debt issuance costs																																			-46,528,000	-21,455,000
acquisition of businesses, contingent consideration obligations at fair value
depreciation and amortization																																				13,445,000
(gain) loss on sale of marketable securities
amortization of debt discounts and debt issuance costs																																				9,370,000
acquired in-process research and development																																				140,732,000
income taxes payable																																				14,810,000
acquisition of intangible assets																																				-5,610,000
decrease (increase) in restricted cash
cash settlement of call options
acquisition of businesses, contingent consideration at fair value																																				91,027,000
settlement of convertible debt, equity issued

We provide you with 20 years of cash flow statements for Bausch Health Companies stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Bausch Health Companies stock. Explore the full financial landscape of Bausch Health Companies stock with our expertly curated income statements.

The information provided in this report about Bausch Health Companies stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.